CDSCO (India)
NOTICE
Clarification on the submission of applications for grant of Permission to Import and Market New Drugs not approved anywhere in the world, wherein phase III Global Clinical Trials (GCT) are ongoing or completed with participation of Indian subjects under the New Drugs and Clinical Trials Rules, 2019
Published: 8/10/2026Detected: 9/4/2026
Summary preview
Clarifies the regulatory submission pathway for seeking Permission to Import and Market new drugs that are not approved anywhere globally when Phase III global clinical trials are ongoing or have been completed with…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountclinical
safety
labeling
manufacturing
quality
#CDSCO
#Permission to Import and Market
#new drugs
#Phase III global clinical trials
#New Drugs and Clinical Trials Rules, 2019
Official Source Document Source Verified
Access the original document directly from INDIA CDSCO.
More from CDSCO (India)
- 28.10.2026 G.S.R. 954(E)_Draftâ Amendment of Rule 43A of the Drugs Rules, 1945 to include various ICDs/Port/SEZs for the import of Drugs/ Medical Devices/ Cosmetics in India10/28/2026
- 28.10.2026 G.S.R. 955(E)_Draft Notification for amendment in the Drugs Rules, 1945 for requirement of an authorised person responsible for batch release of product10/28/2026
- 2026.10.28 G.S.R. 951(E)_Notification regarding rationalization of shelf life under Rule 31 of Drugs Rules, 194510/28/2026
- Appointment of Central Compounding Authority Order10/28/2026
- Misleading or false claims of the product FatX solution registered under COS-2 vide RC no. RC/COS-003300 by the firm M/s Tekno Midas Aesthetics10/28/2026